Literature DB >> 19372178

The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.

Georg Maschmeyer1.   

Abstract

Isolation of patients at risk of invasive mould infection might be suitable for the reduction of invasive aspergillosis or zygomycosis, if combined with high-efficiency particulate air filtration. Prophylactic wearing of filtering masks of N95 or FFP2 standards has not yet been demonstrated to be efficacious in reducing invasive mould infections outside of scenarios with excessive contamination of room air by fungal spore-loaded dust. The oral broad-spectrum antifungal azoles posaconazole and voriconazole offer protection against invasive Aspergillus infections in severely neutropenic leukaemia patients and allogeneic haematopoietic stem cell transplant recipients; however, their routine use might result not only in considerable side effects, but also in the spread of multi-azole-resistant Aspergillus species, so that careful selection of suitable high-risk patient populations is mandatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372178     DOI: 10.1093/jac/dkp084

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  A Preliminary Study of the Comfort in Patients with Leukemia Staying in a Positive Pressure Isolation Room.

Authors:  Wun-Yu You; Tzu-Pei Yeh; Kwo-Chen Lee; Wei-Fen Ma
Journal:  Int J Environ Res Public Health       Date:  2020-05-22       Impact factor: 3.390

Review 2.  Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Authors:  Sibylle C Mellinghoff; Jens Panse; Nael Alakel; Gerhard Behre; Dieter Buchheidt; Maximilian Christopeit; Justin Hasenkamp; Michael Kiehl; Michael Koldehoff; Stefan W Krause; Nicola Lehners; Marie von Lilienfeld-Toal; Annika Y Löhnert; Georg Maschmeyer; Daniel Teschner; Andrew J Ullmann; Olaf Penack; Markus Ruhnke; Karin Mayer; Helmut Ostermann; Hans-H Wolf; Oliver A Cornely
Journal:  Ann Hematol       Date:  2017-12-07       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.